Completed PHASE3 INTERVENTIONAL 2-arm NCT04830813

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients With Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)

Sponsor: Chipscreen Biosciences, Ltd.

Conditions Small Cell Lung Cancer

Interventions Chiauranib Placebo

Updated 9 times since 2021 Last updated: Dec 4, 2024 Started: Mar 5, 2021 Primary completion: Apr 1, 2024 Completion: Apr 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Small Cell Lung Cancer and is currently completed. Chipscreen Biosciences, Ltd. leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Jan 2025 — Present [monthly]

Completed PHASE3

Status: Recruiting → Completed
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE3
Mar 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2022 — Mar 2023 [monthly]

Recruiting PHASE3
May 2021 — Jun 2022 [monthly]

Recruiting PHASE3

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chipscreen Biosciences, Ltd.

Data source: Chipscreen Biosciences, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China